Dino Mustafić

February 27, 2026 Off

AI and job cuts: What the block layoffs signal for pharma and beyond

In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to artificial intelligence (AI) and automation — not just general cost-cutting. The biggest recent example comes from fintech firm Block Inc., which announced plans to cut over 4,000 jobs — roughly 40 % of its workforce — as AI tools reshape how it builds and runs its business, according to multiple news reports. What about pharma?

February 26, 2026 Off

Three days, three signals: What some of the recent pharma deals and earnings reveal about 2026 strategy

By Dino Mustafić

A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.

February 26, 2026 Off

Hikma reports revenue rowth, but stock falls on cautious forecast, amid leadership changes

By Dino Mustafić

UK-based Hikma Pharmaceuticals posted higher annual revenue and strong performance in its injectables segment, but investors reacted negatively to its outlook, sending shares to a three-year low.

February 26, 2026 Off

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

By Dino Mustafić

GlaxoSmithKline has entered into an agreement to acquire Canadian clinical-stage biotech 35Pharma Inc. for $950 million in cash, expanding its respiratory and cardiovascular pipeline, according to regulatory filings and the company’s announcement.

February 26, 2026 Off

Gilead Sciences buys Arcellx for $7.8B, doubling down on CAR-T oncology strategy

By Dino Mustafić

Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers

February 26, 2026 Off

The ADC arms race: payload power vs targeting precision

By Dino Mustafić

Over the past decade, antibody-drug conjugates (ADCs) have emerged as a high-impact class of cancer therapies, blending the selectivity of antibodies with the potency of cytotoxic payloads. But as the modality matures, a structural tension is becoming clear: should innovation focus on chemical escalation of payloads and linkers, or on biological precision of target engagement?

February 25, 2026 Off

ELRIG strenghtens scientific and early career leadership as drug discovery network expand

By Dino Mustafić

The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,

February 25, 2026 Off

Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?

By Dino Mustafić

Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…

February 25, 2026 Off

Sandoz reports 7% revenue growth in 2025, expands biosimilars and projects stronger 2026 outlook

By Dino Mustafić

Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.

February 24, 2026 Off

Promatix’s lead asset ADC for colorectal cancer has positive preclinical data

By Dino Mustafić

Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.